SCHEMBL4437064

SCHEMBL4437064

Cc1ccccc1C(=O)c1cnc(NC(C2CCNCC2)S(=O)(=O)c2ccc(Cl)cc2)s1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 5/20 0.42
MAPK13 O15264 3/20 0.42
MAPK12 P53778 3/20 0.42
MAPK11 Q15759 3/20 0.42
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
PRNP P04156 1/20 0.37
FLT1 P17948 1/20 0.37
FLT4 P35916 1/20 0.37
KDR P35968 1/20 0.37
MAPT P10636 1/20 0.37
LCK P06239 1/20 0.37
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4423515 0.92 MAPK13 (0.41) MAPK14MAPK13MAPK12MAPK11NPC1
SCHEMBL4426968 0.90 MAPK13 (0.44) MAPK14MAPK13MAPK12MAPK11NPC1
SCHEMBL4427053 0.89 MAPT (0.41) MAPK14MAPK13MAPK12MAPK11SMN1; SMN2
SCHEMBL4427490 0.88 CCR8 (0.39) MAPK14MAPK13MAPK12MAPK11NPC1
SCHEMBL4428635 0.87 MAPK14 (0.37) MAPK14MAPK13MAPK12MAPK11SMN1; SMN2
SCHEMBL4437429 0.87 CCR8 (0.35) MAPK14MAPK13MAPK12MAPK11NPC1
SCHEMBL4426937 0.87 HDAC3 (0.35) MAPK14MAPK13MAPK12MAPK11SMN1; SMN2
SCHEMBL4430314 0.86 MAPK13 (0.37) MAPK14MAPK13MAPK12MAPK11
SCHEMBL4429774 0.85 CCR8 (0.35) MAPK14MAPK13MAPK12MAPK11SMN1; SMN2
SCHEMBL4426961 0.85 MAPK13 (0.39) MAPK14MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1656374-B1 THIAZOLE DERIVATIVES AS NPY ANTAGONISTS HOFFMANN LA ROCHE (CH) 2009-03-11 EP claimed
US-7265109-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2007-09-04 US claimed
EP-1656374-A1 THIAZOLE DERIVATIVES AS NPY ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-05-17 EP claimed
US-20050038073-A1 Thiazole derivatives HOFFMAN-LA ROCHE INC. 2005-02-17 US claimed
WO-2005014593-A1 THIAZOLE DERIVATIVES AS NPY ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-02-17 WO claimed
EP-1656374-B1 THIAZOLE DERIVATIVES AS NPY ANTAGONISTS HOFFMANN LA ROCHE (CH) 2009-03-11 EP disclosed
EP-1656374-A1 THIAZOLE DERIVATIVES AS NPY ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-05-17 EP disclosed
US-20050038073-A1 Thiazole derivatives HOFFMAN-LA ROCHE INC. 2005-02-17 US disclosed
WO-2005014593-A1 THIAZOLE DERIVATIVES AS NPY ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038073-A1 Thiazole derivatives NPY4R, NPY1R, NPY2R MAPK14 1746/4885MAPK13 1930/4885MAPK12 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.